The company said that the trial data will be used to apply for CE marking for the SeptRx Intrapocket PFO Occluder (IPO).

SeptRx IPO is designed for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO).

SeptRx CEO Scott Russell said early results look very encouraging, building on the patient outcomes from their first-in-human study.

"In the coming months we will be expanding our trial into additional centers and introducing our larger, 19-mm device into the trial," Russell said.